Treatment for Respiratory Aspiration

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Respiratory Aspiration+3 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial compared the accuracy of the AlignRT system with the ExacTrac system in delivering DIBH to left-sided breast cancer patients.

Eligible Conditions
  • Respiratory Aspiration
  • Abdominal Cancer
  • Thoracic Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: 1 month

1 month
To determine Vision Radiation Therapy (VRT) surface monitoring threshold
To determine planning target volume margin by investigating tumor residual motion in VRT-DIBH
To determine planning target volume margin by investigating tumor residual motion in VRT-DIBH (Vision Radiation Therapy- Deep Inspiration Breath-hold).
To investigate the feasibility of applying (DIBH)Deep Inspiration Breath-hold for tumor image (for lung/liver cancer SBRT)
To investigate the feasibility of applying VRT-DIBH (Vision Radiation Therapy- Deep Inspiration Breath-hold) to lung/liver cancer SBRT(Stereotactic Body Radiotherapy Treatment) using descriptive statistics.

Trial Safety

Trial Design

0 Treatment Group

10 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 month

Who is running the clinical trial?

Vision RT LimitedUNKNOWN
University of Texas Southwestern Medical CenterLead Sponsor
943 Previous Clinical Trials
606,172 Total Patients Enrolled
1 Trials studying Respiratory Aspiration
459 Patients Enrolled for Respiratory Aspiration
David Parsons, PHDPrincipal InvestigatorUT Southwestern Medical Center

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patient with presumed pulmonary function capable of holding breath for at least 30 seconds - later to be confirmed.
You are willing and capable to provide informed consent to participate in the protocol.
You must be willing to comply with all required pretreatment evaluations.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.